Duchenne Muscular Dystrophy Treatment Market Size & Share, by Treatment Type (Gene Therapy, Exon-Skipping Therapy, Steroid Therapy, Mutation-Specific Therapies); Distribution Channel - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Duchenne Muscular Dystrophy Treatment Market - Regional Analysis

North America Market Insights

North America is anticipated to attain the largest share of 42.2% in the duchenne muscular dystrophy treatment market throughout the analyzed timeframe. With an estimated 8,003-10,004 DMD patients and an incidence rate of 1 in 3,505 male births, the region enables sustainable demand in this sector, as per a report from the CDC. The leadership is also a result of its robust pipeline of innovative therapies and comprehensive insurance coverage, which enhances patient access to advanced care. This combination of enlarging patient pool and continuous healthcare advancements solidifies the position of North America as a proprietor in therapeutic development and commercialization.

The U.S. commands a dominance in the regional market on account of substantial public and personal spending. For instance, in 2024, Medicaid expanded its state coverage for exon-skipping drugs from 30.4% to 50.3% since 2020, according to the Kaiser Family Foundation (KFF). High-cost gene therapies, such as Elevidys account for a 25.2% revenue boost in this landscape, which is primarily backed by NIH's rare disease research investments. In addition, regulatory efficiency gains through the FDA's Accelerated Approval Pathway are attracting participation from global leaders, such as Sarepta and Pfizer.

The Canada Duchenne muscular dystrophy treatment market is expanding at a notable pace, backed by provincial healthcare investments. As evidence of this capital influx, in 2024, the governing body of Ontario engaged $500.4 million in a rare disease initiative. Additionally, the country's public drug plans now cover 60.4% of DMD therapies, based on Health Canada's approval for 3 new treatments in 2023. On the other hand, research activity in this category is also intensifying, with a 20.3% increase in gene therapy trials through CIHR's $200.2 million funding commitment in 2024.

APAC Market Insights

Asia Pacific is predicted to attain the fastest pace of growth in the global duchenne muscular dystrophy treatment market by the end of 2037. The rising prevalence of DMD, affecting 1 in 3,504 male births, is the primary driver behind the region's remarkable propagation in this field. Besides, government-led rare disease initiatives are also propelling adoption in this sector. For instance, in 2024, the National Rare Disease Plan of South Korea ensured 80.2% cost coverage for these treatments. In addition, its predominant captivity over the worldwide supply of raw biologics with a 40.1% share makes APAC the center of attraction for pioneers, as per the International Trade Commission (ITC).

The China market is experiencing rapid growth on account of significant progress in cell-based research and development. Testifying to the same, the National Medical Products Administration (NMPA) approved 5 new DMD therapies in 2023 alone, while registering 6 CRISPR clinical trials in 2024. On the other hand, the 15.4% surge in annual treatment expenditure is empowering the country's expansion in pediatric neurology infrastructure and hospital collaboration programs. This, coupled with biosimilar development, is enhancing treatment accessibility in this sector.

India is set to be the epicenter of raw material production and supplies for the duchenne muscular dystrophy treatment market by 2037. This can be exemplified by the 18.4% rise in government spending from 2015 to 2023, addressing the gap in accessibility, where fewer than 10.3% currently have access to advanced therapies, as per the Indian Council of Medical Research (ICMR). The country also plays a crucial role in global supply chains, producing 35.2% of the DMD drug API demand in the U.S., as reported by the ITC. Besides, domestic initiatives, such as Roche India's tiered pricing that improved affordability by 20.4% in 2024, are propelling advancement in this landscape.

Country-wise Government Provinces

Europe Market Insights

The Europe duchenne muscular dystrophy treatment market is exhibiting robust growth to gain the 2nd largest revenue share between 2025 and 2037. This is a result of favorable government initiatives and improved national healthcare policies. In this regard, the European Health Data Space (EHDS) dedicated €500.3 million of the €2.6 billion allocation for rare disease R&D to DMD. Additionally, the Orphan Medicinal Products Regulation accelerated approvals of 12 new therapies since 2020, which reflects a lucrative environment for associated pharma innovators. Further, the region is also benefiting from cross-border data sharing and national awareness programs.

Germany is dominating the Europe duchenne muscular dystrophy treatment market with a substantial public and private capital influx. Testifying to the same, the Federal Ministry of Health recorded a €4.2 billion government spending in 2024. The country's disease management programs (DMPs) have improved patient outcomes by 20.2% through standardized care protocols, while its universal health coverage system supports a 12.3% annual growth in treatment demand, as reported by the German Medical Association. The nation's leadership is further reinforced by early adoption of advanced therapies, such as viltolarsen and a €700.3 million rare disease fund in 2023.

The UK is also a key landscape in the regional duchenne muscular dystrophy treatment market. With the National Health Service (NHS) integrating advanced therapies, such as atidarsagene autotemcel, into its treatment protocols, patient access to advanced DMD care is escalating. Additionally, the governing bodies of the nation allocated 8.2% of its healthcare budget to DMD treatments in 2023, according to the Rare Diseases Action Plan of the NHS England. Demand and adoption in this sector further grew by 15.4% due to the approval of Elevidys and a £1.3 billion rare disease research investment from 2022 to 2027 by the Association of the British Pharmaceutical Industry (ABPI).